Company Overview
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.31.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +240.6%.
- 5-Year Trend Long-term compounding — revenue CAGR -20.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -20.08% |
| 1 Year: | 240.60% |
Stock Price Performance
| 1 Year: | +37.80% |
| 6 Months: | +26.81% |
| 3 Months: | +34.62% |
| 1 Month: | +30.60% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)76.71 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -20.1% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MNOV MediciNova, Inc. PHARMA | 1.75 | -8.33 | $86.14M | 0.00% | -31.77% | -25.56% | -20.08% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00M | - | 37.50K | - | - | - | - | - | 1.00M | - | - | - | - | 134.60K | 123.32K | 186.98K |
| Operating Income | -2.35M | - | -2.21M | -2.28M | -1.59M | - | -3.39M | -3.20M | -2.84M | - | -3.02M | -2.80M | -3.79M | - | -4.67M | -3.40M | -7.03M | - | -4.98M | -4.18M | -2.65M | -2.92M | -4.51M | -3.73M | -201.53K | -4.31M | -3.60M | -3.41M | -4.09M | -3.90M | -2.96M | -3.30M | -1.15M | -3.14M | -3.05M | -3.31M | -3.20M | -3.61M | -3.38M | -2.84M |
| Net Income | -2.34K | -2.38K | -2.21K | -2.29K | -1.61K | -2.73K | -3.38K | -3.20K | -2.84K | -1.45K | -3.02M | -2.79M | -3.75M | -1.60M | -4.54M | -3.14M | -6.78M | -208.00K | -4.70M | -3.88M | -2.38M | -2.71M | -4.45M | -3.70M | -187.80K | -4.28M | -3.58M | -3.39M | -4.03M | -3.65M | -2.92M | -2.87M | -723.11K | -2.75M | -2.63M | -2.85M | -2.86M | -3.28M | -3.05M | -2.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.09 | -0.07 | -0.07 | -0.08 | -0.07 | -0.06 | -0.06 | -0.01 | -0.06 | -0.05 | -0.06 | -0.06 | -0.07 | -0.06 | -0.05 |
| R&D Expense | 800.00K | - | 600.00K | 700.00K | 500.00K | - | 1.00M | 900.00K | 800.00K | - | 800.00K | 800.00K | 1.20M | - | 1.60M | 1.30M | 2.30M | - | 1.50M | 1.40M | 1.10M | 1.20M | 2.10M | 2.10M | 2.00M | 2.30M | 2.00M | 2.00M | 2.50M | 2.40M | 1.40M | 1.60M | 700.00K | 1.70M | 1.50M | 1.80M | 1.70M | 2.00M | 1.50M | 1.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 802.58K | - | - | - | - | - | - | - | - | 4.04M | - | 1.00M | - | 409.66K |
| Operating Income | - | - | - | - | -21.24M | -17.88M | -16.11M | -10.95M | -4.02M | -9.22M | -8.82M | -10.88M | -13.03M | -15.59M | -14.03M | -14.18M | -10.22M | -14.63M | -9.90M | -12.68M | -13.28M |
| Net Income | -25.69M | -35.69M | -48.90M | -21.92M | -20.37M | -20.19M | -17.73M | -10.96M | -4.03M | -9.20M | -8.85M | -10.87M | -11.16M | -14.68M | -12.94M | -13.85M | -10.13M | -14.07M | -8.57M | -11.05M | -12.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.21 | -0.29 | -0.17 | -0.23 | -0.24 |
| R&D Expense | - | - | - | - | 10.87M | 9.71M | 7.78M | 4.50M | 2.70M | 2.90M | 2.70M | 3.10M | 3.90M | 5.30M | 5.70M | 7.10M | 8.10M | 8.70M | 5.30M | 6.80M | 6.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | 72.93M | 30.79M | 19.57M | 29.55M | 27.27M | 37.91M | 39.81M | 43.42M | 77.22M | 79.21M | 75.42M | 87.41M | 74.15M | 66.27M | 55.88M | 45.60M |
| Total Equity | 4.85M | 8.05M | 1.12M | 4.57M | 7.67M | 135.71M | 100.98M | 66.61M | 48.04M | 40.01M | 24.70M | 23.50M | 14.88M | 25.43M | 22.01M | 32.75M | 34.53M | 38.64M | 73.11M | 74.89M | 71.33M | 83.68M | 70.24M | 62.38M | 52.50M | 41.59M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 19.30M | 19.24M | 28.25M | 15.09M | 4.01M | 6.70M | 11.67M | 22.08M | 24.12M | 27.99M | 62.31M | 63.79M | 60.04M | 71.43M | 18.51M | 51.00M | 40.36M | 30.81M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 9.48M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | 48.23M | 7.29M | 4.69M | 4.12M | 5.26M | 5.15M | 5.28M | 4.78M | 4.12M | 4.31M | 4.09M | 3.73M | 3.91M | 3.89M | 3.37M | 4.02M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | 36.79M | 3.70M | 1.04M | 460.44K | 1.59M | 1.49M | 1.63M | 2.88M | 2.19M | 2.23M | 2.19M | 2.83M | 3.19M | 3.28M | 2.96M | 3.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.01M | -17.70M | -13.31M | -11.86M | -10.65M | - | - | -6.55M | -6.92M | -9.11M | -9.12M | -10.83M | -9.38M | -12.91M | -7.43M | -10.64M | -9.81M |
| Investing Cash Flow | -1.14M | 27.64M | -6.08K | -763.38K | -36.75K | - | - | -84.48K | - | 626.32K | -11.27K | -36.49K | -28.73K | -40.01M | 39.91M | -697 | -2.90K |
| Financing Cash Flow | 18.09M | -926.65K | 155.66K | 1.55M | 13.37M | - | - | 8.67M | 10.80M | 42.81M | 10.62M | 7.11M | 20.78M | 7.92K | - | 0 | 244.02K |
| Capital Expenditure | -16.45K | -18.56K | -6.08K | -83.38K | -41.55K | -3.52K | -2.32K | -84.48K | - | -10.20K | -11.27K | -36.49K | -28.73K | -5.01K | -21.30K | -895 | -2.90K |
| Free Cash Flow | -17.03M | -17.72M | -13.31M | -11.95M | -10.69M | - | - | -6.63M | - | -9.12M | -9.14M | -10.86M | -9.41M | -12.92M | -7.45M | -10.64M | -9.81M |
| Share Buybacks | -81.97K | -37.46K | -8.23K | -58.62K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -1,363.8% | - | - | - | - | - | - | - | - | -253.0% | - | -990.0% | - | -3,242.5% |
| Net Margin % | - | - | - | - | - | - | - | -1,365.8% | - | - | - | - | - | - | - | - | -251.0% | - | -857.2% | - | -2,928.8% |
| ROE % | -18.9% | -35.3% | -73.4% | -45.6% | -50.9% | -81.7% | -75.5% | -73.7% | -15.8% | -41.8% | -27.0% | -31.5% | -28.9% | -20.1% | -17.3% | -19.4% | -12.1% | -20.0% | -13.7% | -21.0% | -28.9% |
| ROCE % | - | - | - | - | - | -49.5% | -59.5% | -59.1% | -13.8% | -35.9% | -24.2% | -28.5% | -32.1% | -20.8% | -18.2% | -19.4% | -12.1% | -20.6% | -15.7% | -24.0% | -31.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Essex Woodlands Management Inc. | 2.25% | 1.11M | $3.67M |
| 2 | Blackrock Inc. | 1.53% | 752.09K | $2.50M |
| 3 | Citigroup Inc. | 1.29% | 635.72K | $2.11M |
| 4 | Vanguard Capital Management LLC | 1.24% | 609.05K | $2.02M |
| 5 | Geode Capital Management, LLC | 1.10% | 539.31K | $1.79M |
| 6 | Vanguard Fiduciary Trust Co | 0.57% | 282.61K | $938.26K |
| 7 | UBS Group AG | 0.45% | 222.20K | $737.70K |
| 8 | Renaissance Technologies, LLC | 0.42% | 205.40K | $681.93K |
| 9 | State Street Corporation | 0.39% | 193.70K | $643.08K |
| 10 | Northern Trust Corporation | 0.29% | 143.66K | $476.97K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MNOV
Two drug-trial updates are expected by year-end from MediciNova - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOWm1PSVRlcDJnZUY0ZER1STdWVFFwU1hfZ2VRQ3ZIUDVOeHp0NlhJWlBiZ0pCVVplVWNfckNxNTdwNG1EdnFGM2pFNVVuSEFBU1NoWHVzVGRwMnNMMENVaGNWLW5RTXI3OWpLajJvN3RsYVhtOERPYVNUcElkS21sUUdZOE5MYVE0cEl5Mj…
MediciNova to Participate in Two Investor Conferences in September - ca.finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPczJ2UE1mbzVFV2pYblFxc0pzT0RiZzMzTHhPeHJ1cUk0S1pOZjM3QkU1VVFKUGVZdWZmbFRHR3N3dm5fMjJSSGlHTVp6dW5Wd1YxeEl1TUxJU3Y0YnJuQWRSQkRvLXBzbi1MbDU0SWc2YzNUS1ZSeVJGLS1FVzNYSEpFVlAwOEJxREJxUG…
MNOV - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5GYWxPbU9WRmFUY3NQUUhOUzZOX1Roc1VzQnpSWG1OaTBJQTgwVzNWOVVOSldwNHdIT3RNQzJCVUNWUDhWS0E?oc=5" target="_blank">MNOV</a> <font color="#6f6f6f">Finviz</font>…
MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Stock News, MNOV Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1VNXBETWdIb3RjYmpRNDg5SWxQWUh3U3hkNUlROEozRmJPN19iamthS1l1NzBqMnJzZVFSYkhmT1ZUejhOQW54R3hJSHFneDFkenpQVEtB?oc=5" target="_blank">MediciNova Inc (NASDAQ: MNOV) Share Price, MNOV Sto…
Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV - tradingview.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNRU56TmtOUGNXN1dVQ0gtdTg0bmEwa0ozUWV2eDhCRHhMcmFXTHRMZU1CT1VacVBqdkFRMThzZXJsSlgyYW1heXMyOHoyU3d4UDNfVWNIeDRGbzgwMm90bzdOWUltX0tITld3SmVWckQ0ZUxwQzg1WVAwMko5YjlQaEhTeXRheFNxbTZob1…
MediciNova (MNOV) ends $30M stock-sale deal after tapping only a fraction of it - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNa1JvMjQyS2dWT25Pek4wc2NsU05SWllXZ3hZQW5laWt1VHdkNHB1ekVxWE9nbzhOUmIxRkhURXJoRElZRHAzc3AwR1R2RERQbDlpZkRsb1RqS3NlaXBxT2VKVHkwRHhoVnNoaGw1NXJDRkFMNkpQOWExMnZuZHNHUDd2S1RtNTRId3VXWk…
MNOV — Frequently Asked Questions
What is the current share price of MediciNova, Inc. (MNOV)?
As of 2026-09-19 21:16 PDT, MediciNova, Inc. (MNOV) trades at $1.75 on NasdaqGM. Its 52-week range is $1.18 to $1.88.
What is the market capitalisation of MNOV?
MediciNova, Inc. (MNOV) has a market capitalisation of $86.14M on NasdaqGM.
What is the P/E ratio of MNOV?
MNOV trades at a trailing price-to-earnings (P/E) ratio of -8.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.39.
What is the return on equity (ROE) of MNOV?
MNOV has a return on equity (ROE) of -25.56%. Its return on capital employed (ROCE) is -31.77%.
Is MNOV a good stock to buy?
This page provides a data-driven analysis of MediciNova, Inc. (MNOV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.